SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma released positive Phase 2 COACH trial data showing its…

Ascendis Pharma · PRESS-RELEASE filed Aug 6, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Aug 6, 2026 at 08:00 ET

Ascendis Pharma released positive Phase 2 COACH trial data showing its TransCon CNP + TransCon hGH combination therapy maintained durable, unprecedented growth (mean AGV at or above the 97th percentile) through Week 78 in children with achondroplasia. The company also reported strong U.S. YUVIWEL launch metrics (170+ patient enrollments, >65% reimbursement approval) and completed target enrollment for the pivotal reACHin trial in infants. These updates reinforce the commercial and clinical momentum for YUVIWEL, which was FDA-approved in February 2026.

  • Combination therapy (TransCon CNP + TransCon hGH) showed mean AGV at or above the 97th percentile at Week 78 in the Phase 2 COACH trial.
  • In the CNP treatment-naïve cohort, mean AGV was 7.73 cm/year with a +1.29 increase in ACH height Z-score over 78 weeks.
  • In the CNP-experienced cohort, mean AGV was 7.67 cm/year with a +1.10 increase in ACH height Z-score over 78 weeks.
  • 100% of 21 enrolled children completed 78 weeks and remain on therapy in the COACH trial.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access